secwatch.observer — SEC 8-K summary
======================================

Issuer:     Schrodinger, Inc. (SDGR)
CIK:        0001490978
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0001490978-24-000071
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Schrödinger Q2 rev $47.3M (+35% YoY); net loss $54.0M; updates FY guidance
--------------------------------------------------------------------------

- Total revenue $47.3M (+35% YoY), software rev $35.4M (+21%), drug discovery $11.9M (+104%). Net loss $54.0M vs income $4.3M YoY.
- FY2024 guidance: software rev growth 6-13%, drug discovery $30-35M, op expense growth 8-10%, cash use above FY2023.
- Co-founded Morphic to be acquired by Lilly for ~$3.2B; Schrödinger holds 834,968 shares and low single-digit royalties.
- Launched predictive toxicology platform with $10M Gates Foundation grant and NVIDIA AI integration.
- Pipeline: SGR-1505 Phase 1 data 1H25; SGR-2921 Fast Track, data 2H25; SGR-3515 Phase 1 started, data 2H25.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1490978/000149097824000071/0001490978-24-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1490978/000149097824000071/sdgr-20240731.htm
  HTML page:      https://secwatch.observer/filing/0001490978-24-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer